OakChart

Pomdoctor Ltd

POMHealthcare·Pharmaceutical Retailers·China·Nano·NASD·Nov 11 • 12:28 PM ET

1.67+0.07 (4.37%)
2026-11-11 18:38 CET
Market cap
13.35 USD m
Revenue, TTM
3.97 USD m
Net income, TTM
-4.93 USD m
Free cash flow, TTM
0.21 USD m
EPS diluted, TTM
-0.71
P/E
-
Compare

Price

POM against its 20, 50 and 200-day averages
2050200
0.0020.0040.0060.0024.4M48.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26POMclose 1.6720-day 1.7750-day 2.36200-day 8.951.67

99.5% under the 52-week high of 341.39 on 8 Dec 2025. 52-week low 0.69 on 21 Oct 2026. Last 15 sessions, 192.1% high to low

Profile

POM
52-week range, 0% of the way up
0.69341.39

PomDoctor Ltd. operates as an online medical services platform, which specializes in chronic disease management and pharmaceutical services. It operates through two segments: Internet hospital and pharmaceutical supply chain. The Internet hospital segment include online consultation and prescription renewal and CDM service. The pharmaceutical supply chain provides other pharmaceutical platforms with supply chain management and platform operation services. The company was founded by Zhenyang Shi and Li Xu on February 01, 2021 and is headquartered in Guangzhou, China.

Employees165
IPOOct 08, 2025
Beta2.99
ATR, 14d0.53
Rel volume0.04
Inst own0.03%

Snapshot

6 groups

Valuation

Index-
Market Cap13.93M
Enterprise Value22.66M
Income-
Sales-
Book/sh-1.47
Cash/sh0.03
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees165
IPOOct 08, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C51.58
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.32
Current Ratio0.35
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-47.90% -10.17%
Sales past 3/5Y15.17% 22.15%
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
EarningsMay 14 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own-
Insider Trans-
Inst Own0.03%
Inst Trans-
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-5.69%
SMA50-29.13%
SMA200-81.35%
Trades-

Technical

Shs Outstand6.34M
Shs Float-
Short Float-
Short Ratio0.13
Short Interest0.25M
52W High341.39 -99.51%
52W Low0.69 142.03%
Volatility20.62% 51.77%
ATR (14)0.53
RSI (14)46.25
Beta2.99
Rel Volume0.04
Avg Volume2.00M
Volume39,041

Performance

Perf Week7.74%
Perf Month-32.79%
Perf Quarter-50.88%
Perf Half Y-78.27%
Perf YTD-90.56%
Perf Year-99.47%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close1.60
Price1.67
Change %4.37%

Peers

Mkt cap
TickerCompanyMkt cap
RDGTRidgetech Inc4.14M
YI111 Inc ADR14.79M
PETSPetmed Express Inc23.41M
LFMDLifeMD Inc81.29M
MNDRMobile health Network Solutions1.17M
HIMSHims & Hers Health Inc4.75B
GDRXGoodRx Holdings Inc1.22B
TDOCTeladoc Health Inc1.65B
AMWLAmerican Well Corp212.33M
UPCUniverse Pharmaceuticals INC7.94M

News

latest 14 of 32
  • POMDOCTOR LIMITED Highlights Real-World Data as a Strategic Foundation for AI-Enabled Healthcare Solutions (PR Newswire)
  • POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement (PR Newswire) +30.22% -14.36%
  • POMDOCTOR LIMITED Advances Strategic Evolution from Traffic Monetization to Value-Based Healthcare Payment (PR Newswire)
  • POMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements (PR Newswire) +20.13% -20.00%
  • POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq (PR Newswire) -15.88%
  • Loading…
  • POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare (PR Newswire) -19.35%
  • POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination (PR Newswire)
  • POMDOCTOR LIMITED Accelerates AI-Enabled Chronic Disease Management and RWD Commercialization (PR Newswire)
  • POMDOCTOR LIMITED Highlights Differentiated "Hardware + AI + Payment" Healthcare Infrastructure Model (PR Newswire) +21.23%
  • POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference (PR Newswire) +5.52%
  • POMDOCTOR LIMITED Initiates U.S. Market Preparation and Unveils Expansion Strategy (PR Newswire)
  • POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine (PR Newswire) +26.01%
  • POMDOCTOR LIMITED Highlights Four-Tier Diversified Revenue Structure (PR Newswire) +25.00%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-32.281-112.923-88.789-56.652-62.371-60.545-183.288
Period2019202020212022202320242025
EPS, quarterly
Period
Sales, annual26.85120.45833.39636.41643.02847.59955.633
Period2019202020212022202320242025
Sales, quarterly
Period
Shares, annual0.3290.3290.3290.3290.3290.3290.386
Period2019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue3.9755.6347.6043.0336.4233.4020.4626.85
Cost of Goods Sold Incl. D&A3.4348.3640.9737.5628.2725.2512.6715.72
Gross Profit0.547.276.635.478.158.147.7811.13
Selling, General and Administrative Excl. Other5.5423.489.908.388.6816.6342.6220.43
Research and Development2.281.790.420.480.530.660.290.70
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.00-16.21-3.27-2.91-0.53-8.49-34.83-9.30
Interest Expense0.131.791.801.952.382.532.031.38
Unusual Expense0.010.290.310.230.003.870.000.00
Net Income Before Taxes-5.11-18.21-5.19-5.22-2.95-14.91-37.16-10.64
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.11-29.57-19.92-20.52-18.64-29.21-37.16-10.64
Net Income From Continuing Operations-4.93-29.57-19.92-20.52-18.64-29.21-37.15-10.62
Net Income-4.93-29.57-19.92-20.52-18.64-29.21-37.15-10.62
EPS (Recurring)-0.71-182.02-59.88-61.89-56.65-80.56-112.92-32.28
EPS (Basic, Before Extraordinaries)-0.71-183.29-60.54-62.37-56.65-88.79-112.92-32.28
EPS (Diluted)-0.71-183.29-60.54-62.37-56.65-88.79-112.92-32.28
EBITDA-5.00-16.19-3.25-2.90-0.53-5.18-31.77-6.15
Non-Operating Income (Expense)0.030.080.19-0.12-0.03-0.03-0.300.04
Other After Tax Adjustments--11.36-14.72-15.31-15.69-14.300.000.00
Stock Option Compensation Expense3.471.71------
Gross Margin-13.0713.9212.7022.3724.3838.0541.44
Operating Margin--29.14-6.88-6.77-1.47-25.41-170.26-34.65
Net Margin--53.16-41.85-47.69-51.18-87.47-181.61-39.56
Shares Outstanding6.950.390.330.330.330.330.330.33
Market Capitalization13.3513.352,022.45-----

Income statement, quarterly

Currency USD, millions
Metric2026S1
Total Revenue3.97
Cost of Goods Sold Incl. D&A3.43
Gross Profit0.54
Selling, General and Administrative Excl. Other5.54
Research and Development2.28
Other Operating Expense0.00
Operating Income-5.00
Interest Expense0.13
Unusual Expense0.01
Net Income Before Taxes-5.11
Income Taxes0.00
Consolidated Net Income-5.11
Net Income From Continuing Operations-4.93
Net Income-4.93
EPS (Recurring)-0.71
EPS (Basic, Before Extraordinaries)-0.71
EPS (Diluted)-0.71
EBITDA-5.00
Non-Operating Income (Expense)0.03
Stock Option Compensation Expense3.47
Gross Margin13.66
Operating Margin-125.88
Net Margin-124.21
Shares Outstanding6.95
Market Capitalization13.35

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments1.371.050.960.380.341.971.54
Short Term Receivables12.372.715.224.901.030.621.52
Inventories1.281.382.201.591.521.140.88
Other Current Assets-----0.260.29
Total Current Assets15.025.148.386.872.894.004.23
Net Property, Plant & Equipment0.180.060.080.000.001.992.06
Total Investments and Advances0.000.000.000.070.080.000.09
Long-Term Note Receivable0.000.00-----
Intangible Assets-0.000.000.000.005.667.86
Other Assets0.191.130.890.050.060.200.11
Total Assets15.396.339.356.993.0311.8514.35
Short Term Debt Incl. Current Port. of LT Debt12.0610.187.994.444.058.775.65
Accounts Payable6.413.475.886.244.773.976.17
Other Current Liabilities12.7510.8910.389.988.3437.684.52
Total Current Liabilities31.2224.5424.2520.6617.1650.4216.34
Long Term Debt53.0450.2550.2847.5249.498.735.59
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.00
Total Liabilities84.2674.7974.5468.1866.6659.1521.93
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.00218.52211.37211.84215.270.000.00
Common Equity-64.96-310.09-298.93-284.05-290.14-47.30-7.60
Total Shareholders Equity-64.96-91.57-87.55-72.22-74.87-47.30-7.60
Accumulated Minority Interest-3.9123.1122.3711.0311.240.000.01
Total Equity-68.87-68.46-65.19-61.19-63.63-47.30-7.59
Total Liabilities & Stockholders Equity15.396.339.356.993.0311.8514.35
Book Value Per Share-168.13-942.48-908.56-863.36-881.85-143.77-23.09
Tangible Book Value Per Share-168.13-942.48-908.56-863.36-881.85-160.99-46.98
Full-Time Employees165156165160-200-
Price to Book Ratio-1.09------
Return on Assets-272.24-254.04-251.13-371.90-392.75-283.71-
Quick Ratio0.440.150.250.260.080.060.20
Current Ratio0.480.210.350.330.170.080.26

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-5.11-18.21-5.19-5.22-2.95-14.91-37.16-10.64
Depreciation0.000.020.020.020.003.313.033.18
Other Funds (Non Cash)4.682.810.500.19-0.123.730.020.04
Funds from Operations-0.43-15.39-4.68-5.01-3.06-7.88-34.10-7.42
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital0.64-5.272.44-1.77-0.215.4529.06-1.22
Cash from Operating Activities0.22-20.66-2.24-6.79-3.27-2.43-5.04-8.64
Capital Expenditures-0.01-0.22-0.01-0.020.000.000.00-0.03
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.010.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.00-0.080.000.00
Purchase of Investments0.000.000.000.000.00-0.080.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.00-0.22-0.00-0.020.00-0.080.00-0.03
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock0.0022.810.000.000.000.000.008.68
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.0022.810.000.000.000.000.008.68
Proceedsfrom Stock Options0.0022.810.000.000.000.000.008.68
Issuance or Reduction of Debt, Net-0.101.962.367.393.340.845.270.82
Change in Long Term Debt-0.05-0.550.660.36-0.04-1.87-0.692.70
Issuance of Long Term Debt0.424.830.830.420.000.040.103.78
Reduction of Long Term Debt-0.47-5.39-0.17-0.07-0.04-1.91-0.79-1.08
Net Financing Active Other Cash Flow0.00-3.350.000.000.000.000.000.00
Other Financing Activities Uses0.00-3.350.000.000.000.000.000.00
Cash from Financing Activities-0.1021.412.367.393.340.845.279.51
Exchange Rate Effect-0.05-0.27-0.00-----
Net Change in Cash0.060.270.120.590.07-1.670.230.84
Free Cash Flow0.21-20.80-2.25-6.80-3.27-2.43-5.04-8.67
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S1
Cash & Short Term Investments0.27
Short Term Receivables1.19
Inventories0.14
Total Current Assets1.60
Net Property, Plant & Equipment0.02
Total Investments and Advances0.00
Other Assets0.03
Total Assets1.65
Short Term Debt Incl. Current Port. of LT Debt1.71
Accounts Payable0.76
Other Current Liabilities2.11
Total Current Liabilities4.58
Long Term Debt8.07
Other Liabilities0.00
Total Liabilities12.65
Non-Equity Reserves0.00
Preferred Stock - Carrying Value0.00
Common Equity-10.22
Total Shareholders Equity-10.22
Accumulated Minority Interest-0.78
Total Equity-10.99
Total Liabilities & Stockholders Equity1.65
Book Value Per Share-1.47
Tangible Book Value Per Share-1.47
Price to Book Ratio-1.09
Quick Ratio0.32
Current Ratio0.35

Cash flow, quarterly

Currency USD, millions
Metric2026S1
Net Income-5.11
Depreciation0.00
Other Funds (Non Cash)4.68
Funds from Operations-0.43
Extraordinary Item0.00
Changes in Working Capital0.64
Cash from Operating Activities0.22
Capital Expenditures-0.01
Net Assets From Acquisitions0.00
Sale of Fixed Assets and Businesses0.01
Purchase or Sale of Investments0.00
Purchase of Investments0.00
Sale Or Maturity of Investments0.00
Other Uses0.00
Other Sources0.00
Cash from Investing Activities-0.00
Cash Dividends Paid0.00
Preferred Dividends (Cash Flow)0.00
Change in Capital Stock0.00
Repurchase of Common Pref Stock0.00
Sale of Common Pref Stock0.00
Proceedsfrom Stock Options0.00
Issuance or Reduction of Debt, Net-0.10
Change in Long Term Debt-0.05
Issuance of Long Term Debt0.42
Reduction of Long Term Debt-0.47
Net Financing Active Other Cash Flow0.00
Other Financing Activities Uses0.00
Cash from Financing Activities-0.10
Exchange Rate Effect-0.05
Net Change in Cash0.06
Free Cash Flow0.21

Revenue breakdown

Medical Apparatus And Instruments MAAI2024: 26.17K 2025: 420.66K
Online Consultation2024: 165.64K 2025: 205.52K
Others2024: 609.04K 2025: 444.80K
Overthecounter OTCMedicines2024: 9.97M 2025: 9.76M
Prescription Drugs2024: 36.05M 2025: 44.75M
Traditional Chinese Medicine TCM2024: 840.80K 2025: 67.72K
China2024: 47.67M 2025: 55.65M
Internet Hospital2024: 12.39M 2025: 20.97M
pharmaceuticals Supply Chain2024: 35.28M 2025: 34.68M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.3M-1.94M
2026-10-15-0.0M-20.66K
2026-09-30-0.0M-19.27K
2026-09-15-0.0M-22.43K
2026-08-31-0.0M-25.46K
2026-08-14-0.0M-28.05K
2026-07-31-0.0M-120.33K
2026-07-15-0.0M-124.57K
2026-06-30-0.0M-123.75K
2026-06-15-0.0M-120.17K
2026-05-29-0.0M-121.89K
2026-05-15-0.0M-119.56K
2026-04-30-0.0M-18.12K
2026-04-15-0.0M-12.58K
2026-03-31-0.0M-11.08K
2026-03-13-0.0M-14.58K
2026-02-27-0.0M-39.46K
2026-02-13-0.0M-40.06K
2026-01-30-0.0M-45.02K
2026-01-15-0.0M-51.66K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-06SEC
2026-11-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-04SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-19SEC
2026-10-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-09SEC
2026-10-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-02SEC
2026-09-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-09-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-04SEC
2026-08-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-27SEC
2026-08-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-10SEC
2026-08-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-03SEC
2026-07-28S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-15SEC
2026-07-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-13SEC
2026-07-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-09SEC
2026-07-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-02SEC
2026-06-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-17SEC
2026-05-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-28SEC
2026-05-28F-6 POSPost-effective amendment to a F-6EF registrationSEC
2026-05-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-14SEC
2026-05-1420-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-303Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-30NT 20-F2025-12-31SEC
2026-04-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-20SEC
2026-04-163Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-08SEC
2026-04-033Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
CITADEL ADVISORS LLC0.31%
UBS Group AG0.04%
Caitong International Asset Management Co., Ltd0.01%
Arax Advisory Partners0.01%
Steward Partners Investment Advisory, LLC0.00%
RHUMBLINE ADVISERS0.00%

Funds

Fund% owned
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. POM. Cached 15 minutes.

Some panels did not load: ratings, insider.